Navigation Links
XBiotech Announces Positive Phase II Clinical Trial Results for Lead Candidate MABp1 in Acne Vulgaris
Date:12/12/2012

AUSTIN, Texas, Dec. 12, 2012 /PRNewswire/ -- XBiotech Inc., a privately held biotechnology company, today announced positive Phase II clinical trial results in the treatment of acne vulgaris.  The trial was conducted as an open label study using XBiotech's lead candidate, True Human™ monoclonal antibody MABp1, in patients with moderate to severe disease.  Patients enrolled in the study demonstrated continual improvement in lesions over the course of therapy, with up to 42 percent reduction in eight weeks. The excellent safety profile of MABp1 demonstrated across multiple therapeutic indications to date, and strong initial results in this trial, provide the basis for further development of the first biologic therapy targeting the inflammatory cytokine IL-1α for acne treatment.

(Logo: http://photos.prnewswire.com/prnh/20121017/MM95359LOGO)

Acne vulgaris is a common skin disease that affects an estimated 80% of Americans at some time during their lives. Twenty percent will have severe acne, which results in permanent physical and mental scarring. Acne vulgaris is America's most common skin disease and is characterized by non-inflammatory, open or closed comedones and by inflammatory papules, pustules, and nodules.

Currently, there are several approved topical and systemic treatments however no biological therapy has yet been approved for the treatment of acne.  The Phase II clinical trial involving the XBiotech proprietary platform technology was a multicenter study, and included leading investigators such as Dr. Ronald Moy, recent President of the American Academy of Dermatology, former Co-Chief of Dermatology, and Chief of Dermatological Surgery at UCLA Medical Center.  

"We believe that our True Human™ monoclonal antibody therapy has the potential to provide a completely new biologic approach to the manag
'/>"/>

SOURCE XBiotech Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Milo Biotechnology Announces FDA Orphan Drug Designation for AAV1-FS344 for Treatment of Duchenne and Becker Muscular Dystrophy
2. Career Confidential Announces Release of New E-book About Using Recruiters
3. Pittcon Announces 2013 Award Recipients; New Award, Robert Boyle Prize for Analytical Science, Added to Technical Program
4. Innosight Announces Leadership Transition
5. My Cleaning Products Announces its Christmas Special, Sells Rusterizer at 20% Less
6. GenScript Announces Collaboration with AMDeC: Seeks to Decrease Biological Research Costs at NYC Area Institutions
7. Sequenom Announces Leadership Appointments
8. Rusty Cage Announces Rusterizer's 30% New Year Special Discount
9. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
10. Verenium Announces $22.5 Million, Five-Year Secured Financing
11. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Industry ... Development, Asia Pacific. In this newly-created position, Gibbs will lead iLab’s business operations ... iLab’s suite of tools. This entails not only introducing iLab to potential partners ...
(Date:9/1/2015)... ... September 01, 2015 , ... Research conducted by Synedgen ... Boston University School of Medicine, Frederick National Laboratory for Cancer Research, and the ... multidisciplinary Open Access journal. , Christopher Ryan PhD, of Synedgen, and Aparajita ...
(Date:9/1/2015)... DUBLIN , September 1, 2015 ... appointment of Sara Mathew to its Board of ... member of the Audit, Compliance & Risk Committee of the ... 1, 2015. Sara previously served as Chairman, President ... retiring in December 2013. During her 12-year tenure at D&B, ...
(Date:8/31/2015)... 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... are for air emission abatement projects in North ... large order for a municipality in the Southern ... competitor,s system that failed to meet the customer,s requirements. This demonstrates ... Derek S. Webb , President and Chief Executive Officer.  ...
Breaking Biology Technology:iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Shire Appoints Sara Mathew to Board of Directors 2
... Researchers from A*STAR Singapore took lead roles in a ... during long-term culture of human embryonic stem cells (hESCs). ... Peter Andrews of the University of Sheffield (UK), Paul ... Oh of Singapore,s Bioprocessing Technology Institute (BTI), and Barbara ...
... November 28, 2011 Elsevier ... analytic solutions, today announced that Thomas H. Zajac ... / MEDai provides solutions for providers, health plans ... profiling, regulatory compliance and clinical surveillance to improve ...
... Pelleve™ Wrinkle Reduction System was featured in a live ... Top dermatologist Dr. Ava Shamban of Santa Monica, CA ... first-hand look at how Pelleve works. The treatment produced ... takes to watch the show. A revolutionary, ...
Cached Biology Technology:Singapore scientists lead human embryonic stem cell study 2Singapore scientists lead human embryonic stem cell study 3Elsevier / MEDai Appoints Tom Zajac as New President 2Elsevier / MEDai Appoints Tom Zajac as New President 3Ellman's Pelleve™ Wrinkle Reduction System featured in "Sexy Eyes" segment on The Doctors 2
(Date:8/3/2015)... Synaptics, Inc. (Nasdaq: SYNA ), the ... members of the executive management team will present to ... Leadership Forum on Tuesday, August 11, 2015 at 1:00 ... the Sonnenalp Resort in Vail, CO. ... information. An audio webcast of the event will be ...
(Date:7/31/2015)... , 31 de julio de 2015 BGI llevará ... www.icg-10.org ) del 22 al 25 de octubre de ... La conferencia celebra su décimo aniversario este año. ... en una de las reuniones anuales más influyentes del ... una de las conferencias científicas más dinámicas, entusiastas y ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 ... www.icg-10.org ) sera organisée par le BGI ... Shenzhen en Chine. ... Depuis son inauguration en 2006, l,ICG est devenue ... dans le domaine des « omiques » et c,est aussi ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... part of the Genome Canada Large-Scale Applied Research Project ... to 16 projects across the country, the researchers in ... with the aim of identifying genes or proteins for ... target cancers and other diseases. The first project, ...
... - New research from the University of Calgary,s Faculty ... diagnosis using an iPhone application with the same accuracy ... technology can be particularly useful in rural medical settings. ... neurologists, regardless of where the physicians and patients are ...
... has revealed how infection by a parasitic fungus dramatically changes ... leonardi ), causing them to become zombie-like and to die ... fungus. The multinational research team studied ants living high up ... research will be published in the BioMed Central open-access journal ...
Cached Biology News:OGI genomics researchers awarded $23 million 2OGI genomics researchers awarded $23 million 3iPhone can diagnose stroke: study 2Zombie ants have fungus on the brain, new research reveals 2
...
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: